drug_type
RELEVANT_DRUG
intervention_type
Biological (CAR-T cell therapy)
drug_description
An autologous, fully human, dual-target CAR-T cell therapy engineered to recognize BCMA (TNFRSF17) and GPRC5D on malignant plasma cells; administered as a single infusion at approximately 1–6 × 10^5 CAR-T cells/kg. Binding to targets triggers CAR signaling, activating T-cell cytotoxicity and cytokine release to lyse tumor cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous dual-target CAR-T cells engineered to recognize BCMA and GPRC5D on malignant plasma cells. Antigen binding activates CAR signaling, leading to T-cell activation, proliferation, cytokine release, and cytotoxic killing of tumor cells, aiming to overcome antigen escape via dual targeting.
drug_name
RD140 injection
nct_id_drug_ref
NCT06655519